Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 23Lymphoma, Mantle-Cell 15Lymphoma, Follicular 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Myeloid, Acute 10Waldenstrom Macroglobulinemia 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Carcinoma, Non-Small-Cell Lung 8Unspecified Adult Solid Tumor, Protocol Specific 7Neoplasms, Plasma Cell 7Lymphoma 7Neoplasms 6Hodgkin Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Congenital Abnormalities 4Burkitt Lymphoma 4Sezary Syndrome 3Recurrence 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

liposomal doxorubicin 2Zidovudine 2Valganciclovir 2tocilizumab 1tanespimycin 1pomalidomide 1ibrutinib 1Vincristine 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multi-centric Castleman's Disease × Bortezomib × Clear all
NCT00092222 2026-06-01

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡